Inhalation Sciences (ISAB) Study result summary

Study findings

• FDA study showed DissolvIt® can predict clinical plasma profiles with high precision, supporting its potential use in developing generic inhalation medicines.

• Study tested a large number of formulations, aligning with FDA guidelines issued in late 2024 that reinforce the need for validated dissolution methods.

Commercialization and business development

• More than 80% of quotation requests now concern CRO services; the quote backlog reached a record SEK 45 million in Q1 2025.

• A SEK 15.2 million share issue, 80% guaranteed, is intended to accelerate commercialization and strengthen presence in key markets.

• Agreement signed with US-based BioLum Sciences, focused on preclinical and clinical inhalation, to address growing US demand.